Benzinga and Yahoo Finance LLC may earn commissions or revenue from some articles through the links below.
On CNBC’s “Mad Money Lightning Round,” Jim Cramer called Oneok (NYSE:OKE) “great” and recommended buying more shares.
On August 5, ONEOK reported better-than-expected GAAP EPS results for its second quarter, posting quarterly earnings of $1.33 per share, beating analysts’ consensus estimate of $1.21 per share.
Don’t miss the next NVIDIA – You can invest in the future of AI for just $10.
**This is a paid advertisement. Please consider the investment objectives, risks, charges and expenses of the Fundrise Innovation Fund carefully before investing. This and other information can be found in the Fund prospectus. Read them carefully before investing.
“The problem with Dollar Tree (NASDAQ:DLTR) is that I think people have realized that the small variety doesn’t work anymore. They’d rather go to Walmart (NYSE:WMT), which is a buy, or Costco (NASDAQ:COST) if they can afford the membership fee,” he said.
On July 16, Piper Sandler analyst Peter Keith downgraded Dollar Tree’s rating from “overweight” to “neutral” and lowered the price target from $143 to $112.
The “Mad Money” host recommended staying away from Dexcom, Inc. (NASDAQ:DXCM). “Dexcom has had a really bad failure. They still haven’t really explained why that is,” he noted.
Dexcom specializes in the sale of continuous glucose monitors.
Trend: Mark Cuban believes that “the next wave of sales will be in real estate and entertainment” – With this new real estate fund you can start with just $100.
On August 5, Baird analyst Jeff Johnson downgraded the company from “outperform” to “neutral” and lowered the price target from $161 to $80.
When asked about KeyCorp (NYSE:KEY), he said: “Definitely keep Key. Key is very, very strong, a fantastic, fantastic bank.”
Cramer said he would buy CRISPR Therapeutics AG (NASDAQ:CRSP).
On August 5, CRISPR Therapeutics reported a smaller quarterly loss than expected.
Read more:
This article Jim Cramer: This Energy Stock Is a Buy, Stay Away from DexCom originally appeared on Benzinga.com
